Loading clinical trials...

Efficacy of DNK333 in Patients With COPD and Cough | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Efficacy of DNK333 in Patients With COPD and Cough

A Multi-centre, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Clinical Efficacy, Tolerability and Safety of Two Weeks Treatment With DNK333 100 mg Bid in Patients With COPD and Cough.

NCT01287325•Novartis

View on ClinicalTrials.gov

Summary

This study evaluates the efficacy and safety of two weeks treatment of DNK333 in patients with COPD and cough.

Eligibility

Age

35 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Mild to moderate COPD
•Forced expiratory volume in 1 second (FEV1) ≥30% predicted
•FEV1/FVC (forced vital capacity) \<70%
•Significant amount of cough and minimal amount of sputum production, both as judged by self reporting

Exclusion Criteria

•Upper or lower airway infection within 4 weeks prior to screening
•COPD exacerbation within 4 weeks prior to screening
•Past history or current diagnosis of congestive heart failure, cirrhosis or hepatic failure
•History of lung cancer or pulmonary resection/thoracic radiotherapy

Locations (2)

Novartis Investigative Site

Zuidlaren, Netherlands

Novartis Investigative Site

London, United Kingdom

Key Dates

Start Date

September 1, 2003

Primary Completion Date

April 1, 2004

Last Updated

February 1, 2011

Enrollment

ACTUAL participants

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DNK333 100 mg twice daily

DRUG

Placebo

DRUG

cfMSC Stem Cell Therapy Targeting COPD

NCT07477600

Chronic Obstructive Pulmonary Disease (COPD)

View study

RECRUITINGPHASE3

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769

Chronic Obstructive Pulmonary Disease

View study

RECRUITINGNA

Probiotics in Pulmonaty Rehabilitation for COPD

NCT06717659

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 1, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy of DNK333 in Patients With COPD and Cough

Inclusion Criteria

Exclusion Criteria

cfMSC Stem Cell Therapy Targeting COPD

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Probiotics in Pulmonaty Rehabilitation for COPD

A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease